Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Glycogen Storage Disease Type II;Pompe's Disease
Conditions
Glycogen Storage Disease Type II;Pompe's Disease
Trial Timeline
Nov 2, 2016 → May 31, 2023
NCT ID
NCT02782741About Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) is a phase 3 stage product being developed by Sanofi for Glycogen Storage Disease Type II;Pompe's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02782741. Target conditions include Glycogen Storage Disease Type II;Pompe's Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03019406 | Phase 2 | Active |
| NCT02782741 | Phase 3 | Completed |
Competing Products
20 competing products in Glycogen Storage Disease Type II;Pompe's Disease